Review

antibody against lifr (Bio-Techne corporation)

Name: antibody against lifr
Brand: Bio-Techne corporation
Rating: 90 (2 reviews)

Bio-Techne corporation is a verified supplier

Bio-Techne corporation manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Bio-Techne corporation antibody against lifr
Antibody Against Lifr, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 90/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibody against lifr/product/Bio-Techne corporation
Average 90 stars, based on 2 article reviews

antibody against lifr - by Bioz Stars, 2026-02

90/100 stars

Images

Image Search Results

Design of the cytokimera GIL-6 and GIO-6. A , schematic illustration of LIF within the trimeric LIF:gp130:LIFR complex, IL-6 in the hexameric 2xIL-6:2xIL-6R:2xgp130 complex, and OSM in the trimeric OSM:gp130:OSMR complex. IL-6 ( red ) was used as a scaffold for the generation of the cytokimera. Site 3 of IL-6 comprising of site 3-1, 3-2, and 3-3 was exchanged by site 3 of either LIF ( green ) leading to GIL-6 or by site 3 of OSM ( blue ) resulting in GIO-6. GIL-6 initially binds to D2/D3 of IL-6R via site 1. Subsequently, GIL-6 binds to D2/D3 of gp130 via site 2 of the IL-6 portion before GIL-6 binds to D3/D4 of the LIFR via site 3 of the LIF portion. GIL-6 forms a tetrameric GIL-6:IL-6R:gp130:LIFR complex. GIO-6 binds either to D2/D3 of the OSMR or to D3/D4 of the LIFR via site 3 of OSM, resulting in the tetrameric GIO-6:IL-6R:gp130:OSMR or GIO-6:IL-6R:gp130:LIFR complexes. B , superposed structure in ribbon and surface view of IL-6 ( red ) (1ALU) including the exchanged regions by LIF ( green ) or OSM ( blue ) for GIL-6 left and GIO-6 right , respectively. GIL-6 modelled in complex of the tetrameric GIL-6:IL-6R:gp130:LIFR complex (PDB 1ALU ; 2Q7N ; 1P9M ) in surface view.

Journal: The Journal of Biological Chemistry

Article Title: Engineered interleukin-6-derived cytokines recruit artificial receptor complexes and disclose CNTF signaling via the OSMR

doi: 10.1016/j.jbc.2024.107251

Figure Lengend Snippet: Design of the cytokimera GIL-6 and GIO-6. A , schematic illustration of LIF within the trimeric LIF:gp130:LIFR complex, IL-6 in the hexameric 2xIL-6:2xIL-6R:2xgp130 complex, and OSM in the trimeric OSM:gp130:OSMR complex. IL-6 ( red ) was used as a scaffold for the generation of the cytokimera. Site 3 of IL-6 comprising of site 3-1, 3-2, and 3-3 was exchanged by site 3 of either LIF ( green ) leading to GIL-6 or by site 3 of OSM ( blue ) resulting in GIO-6. GIL-6 initially binds to D2/D3 of IL-6R via site 1. Subsequently, GIL-6 binds to D2/D3 of gp130 via site 2 of the IL-6 portion before GIL-6 binds to D3/D4 of the LIFR via site 3 of the LIF portion. GIL-6 forms a tetrameric GIL-6:IL-6R:gp130:LIFR complex. GIO-6 binds either to D2/D3 of the OSMR or to D3/D4 of the LIFR via site 3 of OSM, resulting in the tetrameric GIO-6:IL-6R:gp130:OSMR or GIO-6:IL-6R:gp130:LIFR complexes. B , superposed structure in ribbon and surface view of IL-6 ( red ) (1ALU) including the exchanged regions by LIF ( green ) or OSM ( blue ) for GIL-6 left and GIO-6 right , respectively. GIL-6 modelled in complex of the tetrameric GIL-6:IL-6R:gp130:LIFR complex (PDB 1ALU ; 2Q7N ; 1P9M ) in surface view.

Article Snippet: Anti-OSMR (catalog no. BAF4389), LIFR (catalog no. BAF249) (R&D Systems) were diluted 1:2000.

Techniques:

GIL-6 induces JAK/STAT signaling and cellular proliferation via non-natural cytokine receptor complexes. A , proliferation of Ba/F3-gp130, Ba/F3-IL-6R:gp130, Ba/F3-gp130:OSMR, Ba/F3-gp130:LIFR, Ba/F3-IL-6R:gp130:OSMR, Ba/F3-IL-6R:gp130:OSMR, Ba/F3-IL-6R:gp130:LIFR cells without cytokine (−), with 100 ng/ml HIL-6, 10 ng/ml IL-6, 10 ng/ml LIF, 10 ng/ml OSM, 100 ng/ml GIL-6, 100 ng/ml GIO-6 and 100 ng/ml IC7. Data represents mean±S.D. of three independent experiments. For statistics the treated groups were compared with the untreated group by two-way ANOVA including Dunnet’s test for correction in multiple comparison. B , STAT3 activation in Ba/F3, Ba/F3-gp130, Ba/F3-IL-6R:gp130, Ba/F3-gp130:OSMR, Ba/F3-gp130:LIFR, Ba/F3-IL-6R:gp130:OSMR, Ba/F3-IL-6R:gp130:LIFR cells without cytokine (−) and after stimulation with 100 ng/ml HIL-6, 10 ng/ml IL-6, 10 ng/ml LIF, 10 ng/ml OSM, 100 ng/ml GIL-6, 100 ng/ml GIO-6 and 100 ng/ml IC7 for 20 min. C , STAT1, STAT3, STAT5, ERK, and Akt activation in Ba/F3-IL-6R:gp130:LIFR cells with the same conditions as for the STAT3 activation. D , STAT3 activation in heart, liver, and spleen after injection of 20 μg GIL-6 or GIO-6. Mice were sacrificed 30 min after intraperitoneal cytokine injection. Equal amounts of proteins (50 μg/lane) were analyzed via specific antibodies detecting phospho-STAT3 and STAT3. Western blot data shows one representative experiment out of three. E , schematic illustration of IC7. Site 3 of IL-6 ( red ) comprising site 3-1, 3-2, and 3-3 was exchanged by site III of CNTF ( grey ) resulting in IC7. Consequently, IC7 forms tetrameric IC7:IL-6R:gp130:LIFR or IC7:IL-6R:gp130:OSMR complexes.

Journal: The Journal of Biological Chemistry

Article Title: Engineered interleukin-6-derived cytokines recruit artificial receptor complexes and disclose CNTF signaling via the OSMR

doi: 10.1016/j.jbc.2024.107251

Figure Lengend Snippet: GIL-6 induces JAK/STAT signaling and cellular proliferation via non-natural cytokine receptor complexes. A , proliferation of Ba/F3-gp130, Ba/F3-IL-6R:gp130, Ba/F3-gp130:OSMR, Ba/F3-gp130:LIFR, Ba/F3-IL-6R:gp130:OSMR, Ba/F3-IL-6R:gp130:OSMR, Ba/F3-IL-6R:gp130:LIFR cells without cytokine (−), with 100 ng/ml HIL-6, 10 ng/ml IL-6, 10 ng/ml LIF, 10 ng/ml OSM, 100 ng/ml GIL-6, 100 ng/ml GIO-6 and 100 ng/ml IC7. Data represents mean±S.D. of three independent experiments. For statistics the treated groups were compared with the untreated group by two-way ANOVA including Dunnet’s test for correction in multiple comparison. B , STAT3 activation in Ba/F3, Ba/F3-gp130, Ba/F3-IL-6R:gp130, Ba/F3-gp130:OSMR, Ba/F3-gp130:LIFR, Ba/F3-IL-6R:gp130:OSMR, Ba/F3-IL-6R:gp130:LIFR cells without cytokine (−) and after stimulation with 100 ng/ml HIL-6, 10 ng/ml IL-6, 10 ng/ml LIF, 10 ng/ml OSM, 100 ng/ml GIL-6, 100 ng/ml GIO-6 and 100 ng/ml IC7 for 20 min. C , STAT1, STAT3, STAT5, ERK, and Akt activation in Ba/F3-IL-6R:gp130:LIFR cells with the same conditions as for the STAT3 activation. D , STAT3 activation in heart, liver, and spleen after injection of 20 μg GIL-6 or GIO-6. Mice were sacrificed 30 min after intraperitoneal cytokine injection. Equal amounts of proteins (50 μg/lane) were analyzed via specific antibodies detecting phospho-STAT3 and STAT3. Western blot data shows one representative experiment out of three. E , schematic illustration of IC7. Site 3 of IL-6 ( red ) comprising site 3-1, 3-2, and 3-3 was exchanged by site III of CNTF ( grey ) resulting in IC7. Consequently, IC7 forms tetrameric IC7:IL-6R:gp130:LIFR or IC7:IL-6R:gp130:OSMR complexes.

Article Snippet: Anti-OSMR (catalog no. BAF4389), LIFR (catalog no. BAF249) (R&D Systems) were diluted 1:2000.

Techniques: Comparison, Activation Assay, Injection, Western Blot

Biological activity of cytokimeras GIL-6 and GIO-6 is comparable to natural cytokines. A , proliferation of Ba/F3-IL-6R:gp130, Ba/F3-gp130:LIFR, Ba/F3-gp130:OSMR, Ba/F3-IL-6R:gp130:LIFR, Ba/F3-IL-6R:gp130:OSMR cells in the presence and absence of increasing concentrations of GIL-6 (0.002–1000 ng/ml). The EC 50 values were calculated by fitting a non-linear regression curve. One representative experiment out of three is shown. B , proliferation of Ba/F3-IL-6R:gp130:LIFR cells in the presence and absence of increasing concentrations LIF (0.002–50 ng/ml), IL-6 (0.002–30 ng/ml) or IC7 (0.002–1000 ng/ml). One representative experiment out of three is shown. C , proliferation of Ba/F3-IL-6R:gp130, Ba/F3-gp130:LIFR, Ba/F3-gp130:OSMR, Ba/F3-IL-6R:gp130:LIFR, Ba/F3-IL-6R:gp130:OSMR cells in the presence and absence of increasing concentrations of GIO-6 (0.002–1000 ng/ml). One representative experiment out of three is shown. D , proliferation of Ba/F3-IL-6R:gp130:OSMR cells in the presence and absence of increasing concentrations of IC7 (0.002–2000 ng/ml) and proliferation of Ba/F3-gp130:OSMR cells in the presence of OSM (0.001–100 ng/ml). One representative experiment out of three is shown. E , STAT3 and ERK activation in Ba/F3-IL-6R:gp130:LIFR cells without cytokine (−) and after stimulation with increasing amounts of IL-6, LIF, GIL-6 or GIO-6 (0.2, 2, 20, 200 ng/ml) for 20 min. Equal amounts of proteins (50 μg/lane) were analyzed via specific antibodies detecting phospho-STAT3, STAT3, phospho-ERK and ERK. Western blot data shows one representative experiment out of three. F , time-dependent STAT3 activation of Ba/F3-IL-6R:gp130:OSMR cells with OSM (10 ng/ml), IL-6 (10 ng/ml) or GIO-6 (100 ng/ml) and Ba/F3-IL-6R:gp130:LIFR cells with LIF (10 ng/ml), IL-6 (10 ng/ml) or GIL-6 (100 ng/ml) for the indicated time points. Equal amounts of proteins (50 μg/lane) were analyzed via specific antibodies detecting phospho-STAT3 and STAT3.

Journal: The Journal of Biological Chemistry

Article Title: Engineered interleukin-6-derived cytokines recruit artificial receptor complexes and disclose CNTF signaling via the OSMR

doi: 10.1016/j.jbc.2024.107251

Figure Lengend Snippet: Biological activity of cytokimeras GIL-6 and GIO-6 is comparable to natural cytokines. A , proliferation of Ba/F3-IL-6R:gp130, Ba/F3-gp130:LIFR, Ba/F3-gp130:OSMR, Ba/F3-IL-6R:gp130:LIFR, Ba/F3-IL-6R:gp130:OSMR cells in the presence and absence of increasing concentrations of GIL-6 (0.002–1000 ng/ml). The EC 50 values were calculated by fitting a non-linear regression curve. One representative experiment out of three is shown. B , proliferation of Ba/F3-IL-6R:gp130:LIFR cells in the presence and absence of increasing concentrations LIF (0.002–50 ng/ml), IL-6 (0.002–30 ng/ml) or IC7 (0.002–1000 ng/ml). One representative experiment out of three is shown. C , proliferation of Ba/F3-IL-6R:gp130, Ba/F3-gp130:LIFR, Ba/F3-gp130:OSMR, Ba/F3-IL-6R:gp130:LIFR, Ba/F3-IL-6R:gp130:OSMR cells in the presence and absence of increasing concentrations of GIO-6 (0.002–1000 ng/ml). One representative experiment out of three is shown. D , proliferation of Ba/F3-IL-6R:gp130:OSMR cells in the presence and absence of increasing concentrations of IC7 (0.002–2000 ng/ml) and proliferation of Ba/F3-gp130:OSMR cells in the presence of OSM (0.001–100 ng/ml). One representative experiment out of three is shown. E , STAT3 and ERK activation in Ba/F3-IL-6R:gp130:LIFR cells without cytokine (−) and after stimulation with increasing amounts of IL-6, LIF, GIL-6 or GIO-6 (0.2, 2, 20, 200 ng/ml) for 20 min. Equal amounts of proteins (50 μg/lane) were analyzed via specific antibodies detecting phospho-STAT3, STAT3, phospho-ERK and ERK. Western blot data shows one representative experiment out of three. F , time-dependent STAT3 activation of Ba/F3-IL-6R:gp130:OSMR cells with OSM (10 ng/ml), IL-6 (10 ng/ml) or GIO-6 (100 ng/ml) and Ba/F3-IL-6R:gp130:LIFR cells with LIF (10 ng/ml), IL-6 (10 ng/ml) or GIL-6 (100 ng/ml) for the indicated time points. Equal amounts of proteins (50 μg/lane) were analyzed via specific antibodies detecting phospho-STAT3 and STAT3.

Article Snippet: Anti-OSMR (catalog no. BAF4389), LIFR (catalog no. BAF249) (R&D Systems) were diluted 1:2000.

Techniques: Activity Assay, Activation Assay, Western Blot

Cytokimera GIL-6 and GIO-6 are poor inducers of trans -signaling. A , proliferation of Ba/F3-gp130:LIFR cells in the presence and absence of fixed concentrations of sIL-6R (0 or 100 ng/ml) and increasing concentrations of IL-6 (0.002–1000 ng/ml). One representative experiment out of three is shown. B , proliferation of Ba/F3-gp130:LIFR cells in the presence and absence of fixed concentrations of sIL-6R (0 or 100 ng/ml) and increasing concentrations of GIL-6 (0.002–2000 ng/ml). One representative experiment out of three is shown. C , proliferation of Ba/F3-gp130:LIFR cells in the presence and absence of fixed concentrations of sIL-6R (0 or 100 ng/ml) and increasing concentrations of GIO-6 (0.002–2000 ng/ml). One representative experiment out of three is shown. D , proliferation of Ba/F3-gp130:OSMR cells in the presence and absence of fixed concentrations of sIL-6R (0 or 100 ng/ml) and increasing concentrations of GIO-6 (0.002–2000 ng/ml). One representative experiment out of three is shown. E , proliferation of Ba/F3-gp130:LIFR cells in the presence and absence of fixed concentrations of sIL-6R (0 or 100 ng/ml) and increasing concentrations of IC7 (0.002–1000 ng/ml). One representative experiment out of three is shown. F , STAT3 activation in Ba/F3-gp130:LIFR cells without cytokine (−), 10 ng/ml LIF, 100 ng/ml IL-6, 100 ng/ml GIL-6, 100 ng/ml GIO-6 and either with 100 ng/ml sIL-6R (+) or without (/). Equal amounts of protein (50 μg/lane) were analyzed via specific antibodies detecting phospho-STAT3 and STAT3. Western blot data shows one representative experiment out of three. G , STAT3 activation in Ba/F3-gp130:OSMR cells without cytokine (−), 10 ng/ml OSM, 100 ng/ml IL-6, 100 ng/ml GIL-6, 100 ng/ml GIO-6 and either with 100 ng/ml sIL-6R (+) or without (/). Equal amounts of protein (50 μg/lane) were analyzed via specific antibodies detecting phospho-STAT3 and STAT3. Western blot data shows one representative experiment out of three.

Journal: The Journal of Biological Chemistry

Article Title: Engineered interleukin-6-derived cytokines recruit artificial receptor complexes and disclose CNTF signaling via the OSMR

doi: 10.1016/j.jbc.2024.107251

Figure Lengend Snippet: Cytokimera GIL-6 and GIO-6 are poor inducers of trans -signaling. A , proliferation of Ba/F3-gp130:LIFR cells in the presence and absence of fixed concentrations of sIL-6R (0 or 100 ng/ml) and increasing concentrations of IL-6 (0.002–1000 ng/ml). One representative experiment out of three is shown. B , proliferation of Ba/F3-gp130:LIFR cells in the presence and absence of fixed concentrations of sIL-6R (0 or 100 ng/ml) and increasing concentrations of GIL-6 (0.002–2000 ng/ml). One representative experiment out of three is shown. C , proliferation of Ba/F3-gp130:LIFR cells in the presence and absence of fixed concentrations of sIL-6R (0 or 100 ng/ml) and increasing concentrations of GIO-6 (0.002–2000 ng/ml). One representative experiment out of three is shown. D , proliferation of Ba/F3-gp130:OSMR cells in the presence and absence of fixed concentrations of sIL-6R (0 or 100 ng/ml) and increasing concentrations of GIO-6 (0.002–2000 ng/ml). One representative experiment out of three is shown. E , proliferation of Ba/F3-gp130:LIFR cells in the presence and absence of fixed concentrations of sIL-6R (0 or 100 ng/ml) and increasing concentrations of IC7 (0.002–1000 ng/ml). One representative experiment out of three is shown. F , STAT3 activation in Ba/F3-gp130:LIFR cells without cytokine (−), 10 ng/ml LIF, 100 ng/ml IL-6, 100 ng/ml GIL-6, 100 ng/ml GIO-6 and either with 100 ng/ml sIL-6R (+) or without (/). Equal amounts of protein (50 μg/lane) were analyzed via specific antibodies detecting phospho-STAT3 and STAT3. Western blot data shows one representative experiment out of three. G , STAT3 activation in Ba/F3-gp130:OSMR cells without cytokine (−), 10 ng/ml OSM, 100 ng/ml IL-6, 100 ng/ml GIL-6, 100 ng/ml GIO-6 and either with 100 ng/ml sIL-6R (+) or without (/). Equal amounts of protein (50 μg/lane) were analyzed via specific antibodies detecting phospho-STAT3 and STAT3. Western blot data shows one representative experiment out of three.

Article Snippet: Anti-OSMR (catalog no. BAF4389), LIFR (catalog no. BAF249) (R&D Systems) were diluted 1:2000.

Techniques: Activation Assay, Western Blot

CNTF signals via the alternative CNTFR:gp130:OSMR complex but not via IL-6R:gp130:OSMR. A , proliferation of Ba/F3-CNTFR:gp130:LIFR or Ba/F3-CNTFR:gp130:OSMR cells with increasing concentrations of CNTF (0.0002–100 ng/ml). One representative experiment out of four is shown. B , proliferation of Ba/F3-gp130:LIFR or Ba/F3-gp130:OSMR cells in the presence of fixed concentrations of sIL-6R (100 ng/ml) and increasing concentrations of CNTF (0.05–100 ng/ml). One representative experiment out of three is shown. C and D , CNTF dose-dependent STAT3 activation of Ba/F3-CNTFR:gp130:LIFR ( C ), Ba/F3-CNTFR:gp130:OSMR ( D ) cells without cytokine (−) or in the presence of 10 ng/ml LIF or OSM, or with 0.1, 1, 10 or 100 ng/ml CNTF for 20 min. Equal amounts of proteins (50 μg/lane) were analyzed via specific antibodies detecting phospho-STAT3 and STAT3. Western blot data shows one representative experiment out of three. E , proliferation of Ba/F3-gp130, Ba/F3-CNTFR:gp130:LIFR, Ba/F3-CNTFR:gp130:OSMR, Ba/F3-IL-6R:gp130:LIFR or Ba/F3-IL-6R:gp130:OSMR cells without cytokine (−) or in the presence of CNTF (0.5, 5 or 50 ng/ml), LIF (10 ng/ml), OSM (10 ng/ml) or IL-6 (10 ng/ml). Data represents mean ± S.D. of three independent experiments. For statistics, the treated groups were compared with the untreated group by two-way ANOVA including Dunnet’s test for correction in multiple comparisons. F , STAT3 activation Ba/F3-CNTFR:gp130:OSMR cells without cytokine (−), 10 ng/ml LIF, 10 ng/ml CNTF or 10 ng/ml OSM. Equal amounts of proteins (50 μg/lane) were analyzed via specific antibodies detecting phospho-STAT3 and STAT3. Western blot data shows one representative experiment out of three. G and H , CNTF dose-dependent STAT3 activation of Ba/F3-IL-6R:gp130:LIFR ( G ) or Ba/F3-IL-6R:gp130:OSMR ( H ) cells without cytokine (−) or in the presence of 10 ng/ml LIF or OSM, or with 0.1, 1, 10 or 100 ng/ml CNTF for 20 min. Equal amounts of proteins (50 μg/lane) were analyzed via specific antibodies detecting phospho-STAT3 and STAT3. Western blot data shows one representative experiment out of three. I , proliferation of Ba/F3-gp130:LIFR or Ba/F3-gp130:OSMR cells in the presence of increasing concentrations of Hyper-CNTF-IL-6R-Fc (0.02–8000 ng/ml). One representative experiment out of three is shown. J , schematic illustration of CNTF in tetrameric complexes consisting of CNTF:CNTFR:gp130:LIFR, CNTF:CNTFR:gp130:OSMR or CNTF:IL-6R:gp130:LIFR but not CNTF:IL-6R:gp130:OSMR.

Journal: The Journal of Biological Chemistry

Article Title: Engineered interleukin-6-derived cytokines recruit artificial receptor complexes and disclose CNTF signaling via the OSMR

doi: 10.1016/j.jbc.2024.107251

Figure Lengend Snippet: CNTF signals via the alternative CNTFR:gp130:OSMR complex but not via IL-6R:gp130:OSMR. A , proliferation of Ba/F3-CNTFR:gp130:LIFR or Ba/F3-CNTFR:gp130:OSMR cells with increasing concentrations of CNTF (0.0002–100 ng/ml). One representative experiment out of four is shown. B , proliferation of Ba/F3-gp130:LIFR or Ba/F3-gp130:OSMR cells in the presence of fixed concentrations of sIL-6R (100 ng/ml) and increasing concentrations of CNTF (0.05–100 ng/ml). One representative experiment out of three is shown. C and D , CNTF dose-dependent STAT3 activation of Ba/F3-CNTFR:gp130:LIFR ( C ), Ba/F3-CNTFR:gp130:OSMR ( D ) cells without cytokine (−) or in the presence of 10 ng/ml LIF or OSM, or with 0.1, 1, 10 or 100 ng/ml CNTF for 20 min. Equal amounts of proteins (50 μg/lane) were analyzed via specific antibodies detecting phospho-STAT3 and STAT3. Western blot data shows one representative experiment out of three. E , proliferation of Ba/F3-gp130, Ba/F3-CNTFR:gp130:LIFR, Ba/F3-CNTFR:gp130:OSMR, Ba/F3-IL-6R:gp130:LIFR or Ba/F3-IL-6R:gp130:OSMR cells without cytokine (−) or in the presence of CNTF (0.5, 5 or 50 ng/ml), LIF (10 ng/ml), OSM (10 ng/ml) or IL-6 (10 ng/ml). Data represents mean ± S.D. of three independent experiments. For statistics, the treated groups were compared with the untreated group by two-way ANOVA including Dunnet’s test for correction in multiple comparisons. F , STAT3 activation Ba/F3-CNTFR:gp130:OSMR cells without cytokine (−), 10 ng/ml LIF, 10 ng/ml CNTF or 10 ng/ml OSM. Equal amounts of proteins (50 μg/lane) were analyzed via specific antibodies detecting phospho-STAT3 and STAT3. Western blot data shows one representative experiment out of three. G and H , CNTF dose-dependent STAT3 activation of Ba/F3-IL-6R:gp130:LIFR ( G ) or Ba/F3-IL-6R:gp130:OSMR ( H ) cells without cytokine (−) or in the presence of 10 ng/ml LIF or OSM, or with 0.1, 1, 10 or 100 ng/ml CNTF for 20 min. Equal amounts of proteins (50 μg/lane) were analyzed via specific antibodies detecting phospho-STAT3 and STAT3. Western blot data shows one representative experiment out of three. I , proliferation of Ba/F3-gp130:LIFR or Ba/F3-gp130:OSMR cells in the presence of increasing concentrations of Hyper-CNTF-IL-6R-Fc (0.02–8000 ng/ml). One representative experiment out of three is shown. J , schematic illustration of CNTF in tetrameric complexes consisting of CNTF:CNTFR:gp130:LIFR, CNTF:CNTFR:gp130:OSMR or CNTF:IL-6R:gp130:LIFR but not CNTF:IL-6R:gp130:OSMR.

Article Snippet: Anti-OSMR (catalog no. BAF4389), LIFR (catalog no. BAF249) (R&D Systems) were diluted 1:2000.

Techniques: Activation Assay, Western Blot

Review

Structured Review

Images

Similar Products

Image Search Results